|
1
|
Leroy S, Moshous D, Cassar O, Reguerre Y, Byun M, Pedergnana V, Canioni D, Gessain A, Oksenhendler E, Fieschi C, Mahlaoui N, Rivière JP, Herbigneaux RM, Muszlak M, Arnaud JP, Fischer A, Picard C, Blanche S, Plancoulaine S, Casanova JL. Multicentric Castleman disease in an HHV8-infected child born to consanguineous parents with systematic review. Pediatrics 2012; 129:e199-203. [PMID: 22157133 PMCID: PMC3273364 DOI: 10.1542/peds.2010-2739] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Childhood multicentric Castleman disease (MCD) is a rare and unexplained lymphoproliferative disorder. We report a human herpesvirus-8 (HHV-8)-infected child, born to consanguineous Comorian parents, who displayed isolated MCD in the absence of any known immunodeficiency. We also systematically review the clinical features of the 32 children previously reported with isolated and unexplained MCD. The characteristics of this patient and the geographic areas of origin of most previous cases suggest that pediatric MCD is associated with HHV-8 infection. Moreover, as previously suggested for Kaposi sarcoma, MCD in childhood may result from inborn errors of immunity to HHV-8 infection.
Collapse
Affiliation(s)
- Sandrine Leroy
- Department of Pediatric Immunology and Hematology, Necker Hospital, AP-HP, Paris, France.
| | - Despina Moshous
- aDepartment of Pediatric Immunology and Hematology, Necker Hospital, AP-HP, Paris, France;,bParis-Descartes University, Necker Medical School, Paris, France
| | - Olivier Cassar
- Institut Pasteur, Unité d’Epidémiologie et Physiologie des Virus Oncogènes, Département de Virologie, Paris, France;,Centre National de la Recherche, URA3015, Paris, France
| | - Yves Reguerre
- Pediatric Onco-Hematology Unit, St Denis La Réunion, France, EU
| | - Minji Byun
- St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York
| | - Vincent Pedergnana
- Unit of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U980, Paris, France
| | - Danielle Canioni
- bParis-Descartes University, Necker Medical School, Paris, France;,Department of Pathology, Necker Hospital, Paris-Descartes University, Paris, France
| | - Antoine Gessain
- Institut Pasteur, Unité d’Epidémiologie et Physiologie des Virus Oncogènes, Département de Virologie, Paris, France;,Centre National de la Recherche, URA3015, Paris, France
| | - Eric Oksenhendler
- Department of Clinical Immunology, Saint-Louis Hospital, and René Diderot University, Paris, France
| | - Claire Fieschi
- Department of Clinical Immunology, Saint-Louis Hospital, and René Diderot University, Paris, France
| | - Nizar Mahlaoui
- aDepartment of Pediatric Immunology and Hematology, Necker Hospital, AP-HP, Paris, France;,bParis-Descartes University, Necker Medical School, Paris, France
| | - Jean-Pierre Rivière
- Department of Pathology, Centre Hospitalier Regional Félix Guyon, La Réunion, France
| | | | - Matthias Muszlak
- Departement of Pediatrics, Mayotte Hospital, Mamoudzou, Mayotte, France
| | | | - Alain Fischer
- aDepartment of Pediatric Immunology and Hematology, Necker Hospital, AP-HP, Paris, France;,bParis-Descartes University, Necker Medical School, Paris, France;,Institut National de la Santé et de la Recherche Médicale U768, Necker Branch, Paris, France; and
| | - Capucine Picard
- bParis-Descartes University, Necker Medical School, Paris, France;,Institut National de la Santé et de la Recherche Médicale U768, Necker Branch, Paris, France; and,Study Center for Primary Immunodeficiencies Necker Hospital, AP-HP, Paris, France
| | - Stéphane Blanche
- aDepartment of Pediatric Immunology and Hematology, Necker Hospital, AP-HP, Paris, France;,bParis-Descartes University, Necker Medical School, Paris, France
| | - Sabine Plancoulaine
- bParis-Descartes University, Necker Medical School, Paris, France;,Unit of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U980, Paris, France
| | - Jean-Laurent Casanova
- aDepartment of Pediatric Immunology and Hematology, Necker Hospital, AP-HP, Paris, France;,bParis-Descartes University, Necker Medical School, Paris, France;,St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York;,Unit of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U980, Paris, France
| |
Collapse
|
|
2
|
Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol 2008; 59:179-206; quiz 207-8. [PMID: 18638627 DOI: 10.1016/j.jaad.2008.05.001] [Citation(s) in RCA: 163] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2007] [Revised: 04/20/2008] [Accepted: 05/05/2008] [Indexed: 12/11/2022]
Abstract
UNLABELLED Kaposi sarcoma (KS) remains a challenge. Its classic or Mediterranean form tends to be benign. In transplant recipients it may be less so. As part of the AIDS pandemic, of which it was an original defining component, it may be life-threatening. It is due to human herpesvirus-8, which is necessary but not sufficient to produce the disease. KS has a low prevalence in the general population of the United States and United Kingdom, with an intermediate rate in Italy and Greece, and a high one in parts of Africa. In Italy, hot spots include its southern regions, the Po River Valley, and Sardinia, possibly related to a high density of blood-sucking insects. An important challenge is to treat KS patients without immunocompromising them. The potential of effective anti-herpes virus therapy and the use of sirolimus in transplantation recipients have added new opportunities for KS prevention. LEARNING OBJECTIVES At the conclusion of this learning activity, participants should be able to provide the most recent information about Kaposi sarcoma in the context in which it occurs. Its classic or Mediterranean form, its pattern in transplant recipients and others iatrogenically immunosuppressed, and its occurrence as a potentially life-threatening part of the AIDS pandemic will be stressed. Its etiology and transmission will be discussed in detail to facilitate understanding of Kaposi sarcoma and of human herpesvirus-8 infection in the general population of the United States and United Kingdom, in Italy and Greece, and in certain parts of Africa. Its therapy, including the concept of doing it without immunocompromising the patient, will be stressed. New opportunities for Kaposi sarcoma prevention will also be discussed.
Collapse
Affiliation(s)
- Robert A Schwartz
- Department of Dermatology, New Jersey Medical School, Newark, New Jersey 07103-2714, USA.
| | | | | | | |
Collapse
|